Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
114 results about "Immuno therapy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunotherapy, also called biological therapy, is a type of treatment that uses the body's own immune system to fight cancer.
Cancer immunotherapy
InactiveUS7338929B2Increase killStimulate immune responseBiocideNervous disorderDiseaseImmuno therapy
A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.
Owner:PENN STATE RES FOUND
Novel synthetic chimeric fusion transgene with immuno-therapeutic uses
InactiveUS20050053579A1Reducing tumorigenicityPeptide/protein ingredientsAntibody mimetics/scaffoldsInterferon alphaWilms' tumor
The present invention relates to an immuno-therapy conjugate which comprises A-c-B wherein: A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues. The present invention also relates to a vaccine adjuvant comprising the immuno-therapy conjugate of the present invention. The present invention further relates to a method of reducing tumor growth, for inhibiting a viral infection and for improving immune response in a patient.
Owner:GALIPEAU JACQUES +1
Composition and methods for WTI specific immunotherapy
InactiveUS7063854B1Improve responseTumor rejection antigen precursorsPeptide/protein ingredientsAntigenDisease
Owner:CORIXA CORP +1
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
ActiveUS20140356372A1Prevention and reduction of severityImprove efficacyPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenSeverity/Intensity
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy
Owner:NORTHEASTERN UNIV
Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
ActiveUS20100284909A1Effective immunotherapeuticPoor efficacyPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseAmyloid disease
The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
Owner:NEW YORK UNIV
Compositions and methods for WT1 specific immunotherapy
InactiveUS7115272B1Avoid developmentAvoid seizuresPeptide/protein ingredientsPeptide preparation methodsDiseaseImmunogenicity
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise a WT1 polypeptide comprising an immunogenic portion of WT1, wherein said WT1 polypeptide comprises the polypeptide of SEQ ID NO:144. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:UNIV OF WASHINGTON +1
Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
This invention relates to a breakthrough method for pre-sensitizing cancer prior to a therapeutic treatment such as chemotherapy, radiation therapy or immuno-therapy and a novel cytokine mixture used in the method thereof. The cytokine mixture is a serum-free and mitogen-free mixture comprised of specific ratios of cytokines such as IL-1β, TNF-α, IFN-γ and GM-CSF to Interleukin 2 (IL-2), which is effective in inducing cancerous cells to enter a proliferative cell cycle phase thereby increasing their vulnerability to chemotherapy, radiation therapy and immuno-therapy. One such novel cytokine mixture is Multikine®, which can be used alone or in combination with other drugs for the treatment of cancer thereby increasing the success of cancer treatment and the disease free survival of cancer patients.
Owner:CEL SCI CORP
Adoptive immunotherapy for treating cancer
ActiveUS20170349880A1Cancer antigen ingredientsBlood/immune system cellsTumor-infiltrating lymphocytesCancer therapy
The present invention provides methods for producing and / or expanding tumor-infiltrating lymphocytes (TILs) that can be used in adoptive immunotherapy in cancer treatment.
Owner:UNIVERSITY OF LAUSANNE
B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Targeted vectors for cancer immunotherapy
InactiveUS20020177571A1Improve leveling efficiencyBiocidePeptide/protein ingredientsCytokine genesImmuno therapy
This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described.
Owner:UNIV OF SOUTHERN CALIFORNIA
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
ActiveUS10392439B2Improve efficacyImprove securityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenAllergic reaction
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Novel Anti-fibroblast activation protein (FAP) binding agents and uses thereof
InactiveUS20180022822A1Enhance tumor targeting tumorEnhance tumor tumor selectivityAntibody mimetics/scaffoldsAntipyreticAntigenAntigen receptors
Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, and chimeric antigen receptors (CARs) directed against the human FAP antigen as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
Owner:MABIMMUNE DIAGNOSTICS AG
Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
ActiveUS9005579B2Promote growthImprove targetingAntibacterial agentsCompound screeningVirulent characteristicsGram
The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and / or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and / or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
Owner:THE ROCKEFELLER UNIV +1
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
InactiveUS7115261B1Low immunogenicityHybrid immunoglobulinsPeptide/protein ingredientsAntineoplastic ImmunotherapeuticLymphatic Spread
The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody / cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.
Owner:THE SCRIPPS RES INST +1
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
InactiveUS20070036751A1Low immunogenicityHybrid immunoglobulinsPeptide/protein ingredientsLymphatic SpreadAntineoplastic Immunotherapeutic
Owner:THE SCRIPPS RES INST +1
Methods for Treating Allergy and Enhancing Allergen-Specific Immunotherapy by Administering an IL-4R Inhibitor
ActiveUS20180094069A1Improve efficacyImprove securityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenAllergic reaction
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
ActiveUS20150196628A1Improve survivalEnhance immune responseBacterial antigen ingredientsPeptide/protein ingredientsAntigenImmuno therapy
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Methods for Treating Allergy and Enhancing Allergen-Specific Immunotherapy by Administering an IL-4R Inhibitor
ActiveUS20180094070A1Improve efficacyImprove securityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenAllergic reaction
Owner:REGENERON PHARM INC
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
InactiveUS8435529B2Organic active ingredientsPeptide/protein ingredientsAntibody conjugateWilms' tumor
Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.
Owner:IMMUNOMEDICS INC
Novel msln targeting DNA vaccine for cancer immunotherapy
InactiveUS20160317634A1Optimize treatment planStrong immune responseBacteriaCancer antigen ingredientsRecombinant DNADNA
The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
Owner:VAXIMM GMBH
Methods and compositions using immune regulative compound for treatment and management of cancers and other diseases
Methods of treating, preventing and / or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
InactiveUS20130259883A1Peptide/protein ingredientsImmunoglobulins against animals/humansMelanomaImmunotherapeutic agent
A set of phosphorylated peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease. Phosphorylated peptides are also presented for other cancers.
Owner:AGENUS INC
Use of 2,5-Dihydroxybenzene Compounds and Derivatives for the Treatment of Hematological Dyscrasias and Cancer of an Organ
InactiveUS20080125486A1Good curative effectTreatment or prophylaxis of cancerBiocideSenses disorderDiseaseBenzene
The present invention refers to the use of the compound of Formula (I′) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and / or prophylaxis of hematological dyscrasias, including myelodisplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and / or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I″) for the treatment and / or prophylaxis of cancer of an organ.
Owner:ACTION MEDICINES SL
Tumor cell-based cancer immunotherapeutic compositions and methods
InactiveUS20090285861A1Monitor progressInhibit tumor growthVirusesMicrobiological testing/measurementHeat shockOncology
The present invention is based, in part, on the discovery that immunotherapy using cell-based tumor cells genetically modified to express heat shock proteins is particularly effective in preventing, prognosing and / or treating cancer (e.g., ovarian cancer). Accordingly, the invention relates to compositions, kits, and methods for preventing, prognosing and / or treating cancer (e.g., ovarian cancer).
Owner:WU TZYY CHOOU +1
Cancer immunotherapy
InactiveUS20140341978A1Skin cancer vaccineMammal material medical ingredientsAbnormal tissue growthTumor response
We formulated multiple TLR agonists into GVAX (lethally irradiated tumor cell vaccines engineered to secrete GM-CSF). Specifically, GLA and R848, TLR4 and TLR7 / 8 agonists found to be safe in patients, were formulated with GVAX (TEGVAX—for TLR agonists enhanced GVAX), and this formulation was effective in producing anti-tumor responses in 3 different preclinical models, including palpable B16. These anti-tumor responses were correlated with increased CD4 and CD8 T-cells that can secrete IFNγ circulating in the tumor microenvironment as well as significantly higher level of p15E specific CTL mediated cell killing in mice treated with TEGVAX in comparison to controls. When combined with anti-PD-1 antibody, TEGVAX was able to induce regression of established B16 tumors.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Peptide-based immunization therapy for treatment of atherosclerosis
InactiveUS20060233817A1Strong immune responseGood effectPeptide/protein ingredientsDisease diagnosisMammalTherapeutic treatment
The present invention relates to a fragment of apolipoprotein B, for immunization for prophylactic or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, in particular myocardial infarction or stroke, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing ischemic cardiovascular diseases including stroke, using said peptide in an assay, pharmaceutical compositions comprising the peptide. The invention further encompasses a particular peptide sequence aggravating disease, which sequence then can be used for diagnostic assays.
Owner:CARDIOVAX
Compositions and methods for wt1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:CORIXA CORP +1
Methods and Reagents to Treat Tumor and Cancer
This disclosure provides reagent to treat tumor and cancer, and methods of using the same for treating tumor and cancer. One type of the reagent is pro-antibody, which is antibody that can be activated in tumor. Another type of the reagent is a conjugate of sialidase with affinity ligand that can bind to immuno cell surface or a conjugate of sialidase with affinity ligand that can bind to another antibody, therefore provide a sialidase based cancer immuno therapy strategy.
Owner:WANG TIANXIN
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com